CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2004-12-09): Dynavax hepatitis B vaccine results encouraging in trial

Drug & Device Development

Dynavax hepatitis B vaccine results encouraging in trial

Last Updated: 2004-12-09 16:06:58 -0400 (Reuters Health)

NEW YORK (Reuters) - Dynavax Technologies on Thursday said it planned to conduct a broad late-stage clinical program for its experimental hepatitis B vaccine beginning next year following encouraging interim trial results.

The company said its vaccine showed statistically significant superiority in protective antibody responses compared to a GlaxoSmithKline vaccine called Engerix-B in a traditionally more difficult to immunize older adult population.

The interim results measured the response after two doses of the Dynavax drug.

The trial of 88 healthy adults with no detectable hepatitis B virus antibodies is designed to measure response four weeks after administration of the third dose. It is expected to be completed in mid-2005, the company said.

The company previously reported that its vaccine induced more rapid immune response than the Glaxo vaccine in a small mid-stage trial of healthy younger adults.

Dynavax said it expects to begin its phase III program in multiple age groups in mid-2005.

Slide Library
Abstract Library
Live CME Meetings
Slide Library
Abstract Library
Slide Library
Abstract Library
Live CME Meetings
Slide Library
Abstract Library
CLDF Follow Us
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Regional Map
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2015 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.